David W. Anstice
Mr. Anstice has been a director of Alkermes since October 2008. From 2006 to 2008, he served as Executive Vice President of Merck & Co., Inc. with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Merck’s business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck’s Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions with their worldwide ventures, including President, U.S. Human Health; President Human Health, the Americas; and President, Human Health, Europe. Mr. Anstice holds a Bachelor of Economics from the University of Sydney. Mr. Anstice is a member of the United States Advisory Council for the American Australian Association in New York. He is a board member and Vice Chairmen for the United States Studies Centre at the University of Sydney, an Adjunct Professor at the University of Sydney Faculty of Economics and Business, and serves as Chairman and President of the Board for the University of Sydney USA Foundation. Mr. Anstice is also a director of CSL Limited and a non-executive director of NeuClone Pharmaceuticals Pty. Ltd.